Ulcerative colitis
Of the 3 unique stories with a clear outcome, 3 reported it helped (100%). 1 were inconclusive.
These are public YouTube testimonials, not clinical evidence. People who tried BPC-157 and got no result rarely post videos — read this as a sample of the positive end of the distribution.
“she started noticing a dramatic improvement”
“inflammation come down”
“totally changes certain people's behaviors”
“some studies on IBD and ulcerative colitis”
Related research
Stable Gastric Pentadecapeptide BPC 157 Therapy: Effect on Reperfusion Following Maintained Intra-Abdominal Hypertension (Grade III and IV) in Rats.
BPC-157 therapy was shown to effectively counteract reperfusion-induced occlusion syndrome and reduce organ lesions and thrombosis in rats with severe intra-abdominal hypertension. The therapy also promoted vascular recovery and reversed previous ischemia-course lesions.
Stable gastric pentadecapeptide BPC 157 in the treatment of colitis and ischemia and reperfusion in rats: New insights.
BPC-157 treatment restored blood supply to ischemically injured areas in rat models of colitis and ischemia/reperfusion, and rapidly activated collaterals. The treatment also reduced oxidative stress and improved mucosal health in these models.
Stable gastric pentadecapeptide BPC 157 heals cysteamine-colitis and colon-colon-anastomosis and counteracts cuprizone brain injuries and motor disability.
BPC-157 was shown to heal cysteamine-colitis and colon-colon anastomosis, and counteract cuprizone-induced brain injuries and motor disability in rats. This suggests that BPC-157 may be useful in the treatment of inflammatory bowel disease and multiple sclerosis.
Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract.
BPC-157, a stable gastric pentadecapeptide, has been shown to have therapeutic effects on various gastrointestinal tract lesions and injuries, including ulcers, esophagitis, and intestinal anastomosis. It also exhibits anti-inflammatory, angiogenic, and neuroprotective properties.